• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Encapsulated islet transplantation for patients with type 1 diabetes mellitus

    2016-11-12 01:43:34MeirigengQiShusenWangYongWangDepartmentofTranslationalResearchandCellularTherapeuticsDiabetesandMetabolicResearchInstituteBeckmanResearchInstituteoftheCityofHopeDuarteCAUSAOrganTransplantCenterTianjinFirstCenterHospital
    實用器官移植電子雜志 2016年6期

    Meirigeng Qi,Shusen Wang,Yong Wang(. Department of Translational Research and Cellular Therapeutics,Diabetes and Metabolic Research Institute,Beckman Research Institute of the City of Hope,Duarte,CA,USA ;2. Organ Transplant Center,Tianjin First Center Hospital,Tianjin 30092,China ;3. Key Laboratory for Critical Care Medicine of the Ministry of Health,Tianjin First Central Hospital,Tianjin 30000,China ;. Division of Transplantation/Department of Surgery,University of Illinois at Chicago,Chicago,IL,USA

    【Abstract】 Encapsulation of pancreatic islets has been investigated for over three decades to advance islet transplantation outcomes and to defecate the side effects of immunosuppressive medications. Within the numerous encapsulation systems developed, microencapsulation has been investigated most extensively so far. A lot of materials have been used for microencapsulation in different animal models(including non-human primates or NHPs)and some materials have shown to be of immunoprotection to islet grafts without the need for immunosuppression. In spite of the initial success of microcapsules in NHP models,the combined use of islet transplantation(allograft)and microencapsulation has not yet been successful in clinical trials. This concise review consists of two sections∶Brief summary for transplantation of encapsulated pancreatic islets as a treatment for patients with type 1 diabetes mellitus(T1DM), and present challenges and future perspectives.

    【Key words】 T1DM;Islet transplantation;Microencapsulation

    Introduction

    Type 1 diabetes mellitus(T1DM),also known as insulin-dependent diabetes mellitus,is an autoimmune disease that causes a progressive destruction of the insulin-producing pancreatic β-cells1-2. As a result,patients require exogenous insulin to maintain normal blood glucose levels. In patients with T1DM,long-termhyperglycemia often causes complications such as nephropathy,neuropathy,and retinopathy. According to a report from the American Diabetes Association(ADA),there are nearly three million children and adults living with T1DM in the U.S. and millions of others affected worldwide3.Management of T1DM and other associated complications are burdensome to both individuals and to society as a whole. Insulin injection is a common method to directly control blood glucose levels. However,intensive insulin therapy can induce more frequent episodes of hypoglycemic symptoms in certain populations of patients with T1DM4-5.Islet transplantation is considered as an improved way to cure T1DM in comparison with insulin injection and whole pancreas transplantation. Absence of insulin in patients with T1DM forces them to use exogenous insulin to maintain normal blood glucose,which can delay or prevent health complications. Theoretically,exogenous insulin can replace β- cells in islets,but practically,the insulin injection cannot maintain stable blood glucose levels. Pancreatic islet transplantation is a procedure to selectively transplant the endocrine part of a whole pancreas(about 2% of the pancreas mass).In comparison with whole pancreas transplantation,islet transplantation can be conducted via a minimally invasive approach and is associated with minimal or no complications. The islets can be infused via a catheter that has percutaneous portal venous access6.Therefore this procedure can be applied to a wider range of recipients. More importantly,the islet transplantation can provide glycemic control without exogenous insulin and risks of hypoglycemia. The first experimental islet transplantation was conducted in a rodent model in 1972,several years after this a whole pancreas transplantation was initiated in a human patient7. Although islet transplantation has been widely accepted in recent years,the protocol has not obtained a license and is not accepted as a standard clinical treatment. Currently,many islet transplantation centers are planning or initiating license applications for clinical allogeneic islet transplantation.

    Transplantation of encapsulated pancreatic islets as a treatment for patients with T1MD

    Overview of encapsulation

    Cell encapsulation technology is based on the concept of immunoisolation,which was originally presented by Prehn et al. From as early as 1954,Prehn et al.used a type of immunoisolation instrument called the diffusion chamber device8. In that study,the diffusion chamber device was used to prevent the homograft from provoking an immune reaction in the host. Later on this technology was used to protect transplanted cells,known as “artificial cells”9-10. Since islet cells can be isolated and transplanted successfully,the encapsulation technology was soon applied in the field of islet transplantation. Many types of encapsulation technologies have been designed over the last three decades(Figure 1)and investigated in different animals such as mice11,rats12,dogs13-14,and monkeys15-16. These studies demonstrate the feasibility of restoring normoglycemia by implanting allo- and xenografts without immunosuppression. Furthermore,the studies reveal the inconsistency of transplantation outcomes due to differences in encapsulation strategy and in animal models. The studies also suggest that long-term graft survival might depend on enriched and consistent blood supply to the grafts. In the light of the experiences accumulated from the large amount of transplant studies performed in different animal models,scientists and clinicians attempted a trial involving encapsulated allogeneic islet transplantation in patients with T1DM17-20. The following sections address microencapsulation,depict immunology and biocompatibility factors of the devices,outline the approach of local/short-term immunomodulation,and report the trials of clinical encapsulated islet transplantation.

    Microencapsulation

    The main advantages of the microencapsulation system over other encapsulation technologies are its stable mechanical structure,large surface areato-volume ratio,and improved diffusion profile.Due to the flexible and adjustable characteristics,the microcapsules are mostly fabricated from hydrogels. Over the past 30 years,hydrogel including alginate21,poly(hydroxyethyl methacrylate-methyl methacrylate),agarose22,acrylonitrile copolymers,chitosan23,and polyethelene glycol(PEG)24have been frequently used for microencapsulation. To date,the most preferable material for microencapsulation is alginate. The principle of making microcapsules is based on the envelopment of individual islets in a droplet,which is transformed into a rigid capsule by gelification(in the case of alginate beads)followed by polycation coating(in the case of multiple-layered microcapsules).

    Figure 1 Schematic representation of immunoisolation device or bioartificial pancreas. They can be commonly separated into two categories,intravascular and extravascular device. The latter can further be divided into macroencapsulation and microencapsulation devices.Intravascular and extravascular classifications are based on whether or not it is connected directly to the blood circulation. The macroencapsulation and microencapsulation classifications depend on whether it contains one or more islets in the inside

    Alginate,a collective term for a family of polysaccharides synthesized by seaweed and bacteria,is used in a wide range of foods,pharmaceutical products,and other applications25. In molecular terms,alginates are binary linear polysaccharides composed of two monomers,α-L-guluronic(G)and β-D-mannuronic(M)acid,which form M blocks,G blocks,and blocks of alternating sequence(MG)26.In nature,alginates are found to exhibit great variations in composition and arrangement of the two monomers in a polymer chain. Blocks of repeating G units(G blocks)form cavities that bind divalent cations,which cross-link G blocks of other alginate chains27.This in turn allows for the formation of gels as capsules.Hence,G-block sequences are required for the alginate to form a strong gel with divalent ions such as Ca2+,Ba2+and Sr2+. A strong correlation therefore exists between the sequential structure and functional properties of alginates.

    To increase the stability and to reduce the permeability of alginate gel beads,a polycation layer is traditionally added to the alginate gel core28-30. However,the successful use of alginate-polycation capsules as carriers for insulin producing cells in vivo has been hampered by the capsule's lack of biocompatibility as well as their mechanical instability. These disadvantages have made controlled insulin release and immunoprotection of islets difficult to achieve.The major obstacle for stability is swelling,causing an increase in pore size and ultimately breakage. This is caused by the loss of calcium from the calcium-alginate gel by e.g. phosphate and citrate,which can bind calcium,and non-gelling ions such as sodium that over time will exchange some of the calcium in the gel31.

    Immunology and biocompatibility

    Demographics and baseline characteristics within clinical status groups

    Immunology studies the host's defense mechanisms against invasion of foreign organisms; either living or non-living. The immune response is often divided into two categories,innate and acquired immune reaction. The innate immune response is non-specific and exists in all individuals. It doesn't distinguish between different organisms and acts rapidly upon the exposure of foreign invaders. The innate immune reaction typically initiates with cellular mediators such as macrophages and neutrophils. The acquired immune reaction is specific and not actively present in all individuals. This specific immune response requires the recognition of a specific antigen by lymphocytes including T and B cells.

    Biomaterials are not firmly considered as organisms32,however implantation of biomaterials in a host triggers an immune reaction,which involves many components of the immune system. Biocompatibility is commonly defined as the ability of a biomaterial or other medical device to perform its function properly in a specific application with an appropriate response in the host33-34.“Biocompatibility refers to the ability of a biomaterial to perform its desired function with respect to a medical therapy,without eliciting any undesirable local or systemic effects in the recipients or beneficiary of that therapy,but generating the most appropriate beneficial cellular or tissue response in that specific situation,and optimizing the clinically relevant performance of that therapy”33. The immunoisolation device is not constructed solely by material for the main structure and it also contains islet cells. Therefore,in order for the device to be biocompatible,the bioartificial pancreas must carry out its proper function and it must not harm the host. For an immunoisolation device,biocompatibility has been referred to as the degree of fibrosis after implantation into the host. Recently work has focused on the implantation of microcapsules in larger animals,primarily NHPs,to evaluate the biocompatibility of the microcapsules for clinical islet transplantation.

    As noted earlier,alginate is the most commonly used material for islet microencapsulation. The biocompatibility of microcapsules has been tested with the implantation of empty microcapsules in numerous animal models. The peritoneal cavity has been selected as an optimal site for in vivo analysis of microencapsulated islet implantation,as this site can harbor a large volume of microcapsules7. This site is easily accessible during implantation and is relatively safe. It has been reported previously that empty microcapsules,composed of purified alginate,do not elicit any significant foreign body reaction after implantation into the peritoneal cavity of rodents35-36.However,implantation of empty microcapsules into the portal vein of pigs provoke extensive pericapsular cellular overgrowth37. This result indicates that portal vein microcapsule transplantation is incompatible with the current alginate composition.

    The evaluation of the function of microencapsulated islets in large animals is a necessary transit point between scientific studies in rodents and its clinical application for humans. Allotransplantation in large animals has been performed to mimic clinical islet transplantation. Soon-Shiong et al. initially reported the long-term reversal of diabetes in dogs using microencapsulated islet allografts38. Recently,allografts in alginate-PLL microcapsules were tested in the absence of anti-rejection medications in pigs but large-scale studies were not documented39.Wang et al. published work on the normalization of blood glucose levels in dogs for up to 214 days with a single transplantation of microencapsulated allogeneic islets without immunosuppressive medication13. Although the NHP is considered as an optimal allotransplantation model,little is published in terms of microencapsulated islet transplantation.In our previous study,we conducted allogeneic islet transplantations in baboons using the modified PMCG microcapsules. Two diabetic baboons were transplanted with an average of 16 475 IEQ/kg encapsulated islets(2-3 transplants)and neither baboon achieved normoglycemia after transplantation. Evenly distributed microcapsules were observed in the peritoneal cavity.Retrieved microcapsules at 4 weeks post-transplant were intact and free of cellular overgrowth around the microcapsules.

    Due to the shortage of donor tissues for patients with T1DM,xenotransplantation has drawn the attention of research facilities. Most xenotransplantation uses microencapsulated porcine islets as donor tissue.Sun et al. found that microencapsulated porcine islets transplanted into spontaneously diabetic cynomolgus monkeys survived for 120-800 days with no immunosuppression40. Other groups have tested their encapsulated porcine islets in non-diabetic monkeys15-16. It is notable that all of these transplanted porcine islets were encapsulated in alginate-polycation based microcapsules,which is a microcapsule with less antibody permeability.

    In our previous study,human islets encapsulated in Ca2+/Ba2+-alginate microbeads were transplanted into the peritoneal cavity of a diabetic baboon at a dose of 36 000 IEQ/kg. After transplantation,decreased blood glucose and positive C-peptide production were observed up to 2 weeks. Adhesion and clumping of the microcapsules were observed during laparotomy at day 76 post-transplant. Microcapsules that were retrieved at this point presented with fibrotic overgrowth.Xenogeneic tissue can trigger a stronger immune mediated rejection compared to allogeneic tissue,which may explain islet graft dysfunction in this study.Antibody responses against the encapsulated islets were found 20-35 days post-transplant. Similar results were observed in the transplantation of microencapsulated human islets into the peritoneal cavity of diabetic cynomolgus monkey(unpublished data).

    Local or short-term immunomodulation

    As mentioned earlier,a variety of natural and synthetic polymers have been used in islet encapsulation.However,inconsistency and poor long-term results have been a major limitation for clinical application.The graft failure is usually initiated by several factors including poor biocompatibility of the implanted materials,hypoxic conditions for islets inside of the capsules,and incomplete immunoprotection41-42. Thus,local or short-term immunomodulation and a non-systematic immunosuppressive treatment have been investigated to improve the encapsulated islet transplant outcomes.

    Biocompatibility of capsules is crucial for the long-term survival of the islet graft. Study showed that a 10-day immunosuppressive medication regimen significantly reduced the fibrotic overgrowth around the intraportally implanted empty microcapsules43. Our group also tested the beneficial effects of 2-week long T-cell directed immunosuppressive medication and anti-inflammatory agents(TNF-α blocker)on the biocompatibility of Ca2+/Ba2+-alginate microbeads in cynomolgus monkeys. The results showed that the medications could only prevent fibrotic overgrowth on the surface of the implanted empty microbeads for as long as the medications were administered. This suggests that the extended use of immunosuppressants may have to be administrated to make the Ca2+/Ba2+-alginate microbeads biocompatible,which diminishes the goal of the encapsulation strategy(unpublished data).

    Incomplete immunoprotection is mainly caused by the uncontrollable passage of pro-inflammatory cytokines and other immunoreactive molecules with low molecular weights,such as IL-1β(17.5 KD)and TNF-α(51 KD)through the biopolymer membrane44-45.

    Therefore,strategies to block those cytokines have been studied in recent years to improve the graft survival after encapsulated islet transplantation. In a recent study,a peptide inhibitor for the cell surface IL-1 receptor(IL-1R)was conjugated to the hydrogel for capsules to block the interaction between the immobilized cells and the cytokines46. In another strategy,Sertoli cells were used in co-encapsulation with islets cells.These cells are located in the convoluted seminiferous tubules of testes and have been shown to inhibit T and B cell proliferation and IL-2 production47.Co-transplantation of islets with Sertoli cells were shown to have varying protective effects on graft survival in allo-48,concordant(rat to mouse)and discordant(fish to mouse)xeno-49-50,and autoimmune51transplant models. Study showed that the Sertoli cells improve the functional performance of alginate-PLL microencapsulated islets in xenotransplant models(rat-mouse)52. However,this approach has not advanced significantly enough to be used in clinical trials.

    Encapsulated islet transplantation in patients with T1DM

    Table 1 lists the clinical trials of encapsulated islets transplanted in patients with T1DM. Soon-Shiong et al. reported a successful human encapsulated islet transplant in a diabetic patient who was receiving immunosuppression for a functioning kidney graft17.In the study,a total of 15 000 IEQ/kg alginate-PLL encapsulated islets were implanted intraperitoneally.Insulin independence was demonstrated for 9 months after the procedure,with tight glycemic control noted.Scharp et al. subcutaneously implanted a PAN-PVC macroencapsulation device containing allogeneic islets into 9 patients53. The results concluded that macroencapsulated human islets could survive at the subcutaneous site and that semi-permeable membranes can be designed to protect against both allogeneic immune responses as well as the autoimmune reactions of patients with T1DM.

    Calafiore et al. transplanted alginate-PLO microcapsulated islets in a human clinical trial without immunosuppression20. In 2006,the results of the first two patients were published and both patients showed increased C-peptide serum levels,as a measure of islet graft function. Several weeks post transplantation,these two patients presented with an ephemeral incline in exogenous insulin consumption20. In 2011,the same group published the results of encapsulated islet transplantation in 4 patients,which included the follow-up results of the initial two patients reported in 2006 and two other patients transplanted afterwards54.So far,the results from 4 patients have been reported.In all cases the group observed no side effects of the grafting procedure,nor any evidence of immune sensitization. All patients exhibited a lower intake of exogenous insulin,approximately half of the pre-transplantation consumption levels.

    Tuch et al. transplanted allogeneic islets encapsulated in Ba2+-alginate microbeads into four diabetic patients without immunosuppression. C-peptide was present on day one after transplantation,but disappeared within a period of one to four weeks. In a recipient of multiple islet infusions,C-peptide was detected at 6 weeks after the third infusion and remained detectable for 30 months. Neither insulin requirement nor glycemic control was altered in any of the patients18.

    From 2005 to 2006,two companies,Amcyte,Inc.and Novocell,Inc. announced clinical trials involving encapsulated islet transplantation in patients with T1DM. Amcyte,Inc. planned to conduct clinical trials in twelve patients using islets encapsulated in alginate-PLL microcapsules. These microcapsules were further embedded into a macrocapsule for implantation.Another company,Novocell,Inc.(current name ViaCyte,Inc.),initiated phase 1/2 clinical trials of PEG-encapsulated islet allograft implantation in patients with T1DM. Twelve patients were enrolled in this clinical trial. However,this particular study was terminated. Currently,there is limited information available regarding these two clinical trials.most recent newsletter from the website,a registration study has been launched in 2013 for phase 2b/3 clinical trials,in which 30 patients were enrolled. The LCT product,DIABECEL@,is expected to be commercially available in 201619.

    Most recently,Jacobs-Tulleneers-Thevissen et al.published work on transplantation of Ca2+/Ba2+-alginate microbeads containing allogeneic islets in a patient56. The alginate microbeads were harvested 3 months after transplantation and were conglomerated in the peritoneal cavity. Another report announced a commercial product of the macroencapsulation device called the Cell Pouch SystemTM. This device can be subcutaneously implanted. The device has a unique ability of releasing anti-rejection drugs locally. The Cell Pouch SystemTMis currently preparing for clinical trials.

    The future perspectives

    At present,there is a large amount of islet encapsulation-related research in progress around the world trying to eliminate the use of immunosuppressants in patients with T1DM. This research is largely uncoordinated and a well-documented systematic analysis of the various capsule types has not been completed. The correlation between NHPs and human subjects in biocompatibility of device and function of transplanted islets is poorly demonstrated.Despite the numerous clinical trials conducted by academic institutes and biotechnological companies,encapsulated islet transplantation has not been perfected18-20,54,56. With regards to the mixed set of results,there are three main factors limiting the progression of microencapsulated islet transplantation towards clinical application. First,the variability of raw materials in the manufacturing process has impeded the development of a reliable microencapsulation system. Second,current biocompatibility testing relies heavily on in vivo rodent models,which does not

    Table 1 Encapsulated islet transplantation in patients with T1DM

    Xenotransplantation has attracted much attention in the field of islet transplantation. In the light of such consideration,transplantation of microencapsulated xenogeneic islets,especially porcine islets,has commenced in patients with T1DM. In 1996,Living Cell Technologies(LCT),a company based in New Zealand,initiated a clinical trial involving encapsulated porcine islet transplantation. In this trial,porcine islets were encapsulated in alginate-PLO microcapsules and implanted into the peritoneal cavity of patients without immunosuppression. Nine and a half years after transplantation,laparotomy of one of the patients showed the presence of microcapsules in the peritoneal cavity,some of which still contained live pig islet cells. However,the majority of cells appeared to be necrotic55. As of now,the company reported in their website that a total of 14 patients with T1DM were enrolled in the phase 1/2 clinical trial of DIABECEL@conducted in New Zealand and Russia19. The first four patients received approximately 10 000 IEQ/kg encapsulated islets and showed an average reduction of 76% in episodes of clinically significant hypoglycemia unawareness after 30-52 weeks of follow-up. Four patients from each of the second and third groups received 15 000 and 20 000 IEQ/kg of encapsulated islets respectively and the follow-up of these particular patients is ongoing. The last two patients have received a dose at 5 000 IEQ/kg and were enrolled to construct the dose ranging data needed to determine a target product profile for phase 3 clinical trials. Based on the strongly support patients with T1DM. Finally,there is a significant inconsistency in results observed among individual laboratories even with the use of similar biomaterials and experimental approaches.

    Taking all these obstacles into account,the development of a centralized in vitro and in vivo testing center in the future would allow for a more comprehensive,consistent,and species-specific examination of biocompatibility for the encapsulation system. A collaborative consortium may need to be organized,which should lead to the standardization in material selections,techniques,animal models,and procedures. Under active collaboration between research facilities,the end goal of providing islet encapsulation as a viable cure for patients with T1DM without immunosuppressant would be achievable.

    Acknowledgements

    The author would like to thank Dr. Igor Lacik and Dr.Berit L. Strand for sharing their knowledge of islet encapsulation and Dr. James McGarrigle for reviewing and editing the manuscript.

    色综合亚洲欧美另类图片| 国产成年人精品一区二区| 国产女主播在线喷水免费视频网站 | 日本av手机在线免费观看| 男女国产视频网站| 亚洲欧洲国产日韩| av免费在线看不卡| 我的女老师完整版在线观看| av又黄又爽大尺度在线免费看| 亚洲18禁久久av| 久久久精品94久久精品| 国产亚洲最大av| av一本久久久久| 听说在线观看完整版免费高清| 18禁在线播放成人免费| 观看美女的网站| 国产成年人精品一区二区| 有码 亚洲区| 国产精品女同一区二区软件| 精品久久久久久久末码| 18禁在线无遮挡免费观看视频| 嘟嘟电影网在线观看| 国产亚洲精品av在线| 日韩人妻高清精品专区| 国产亚洲91精品色在线| 国产精品久久久久久精品电影小说 | 观看美女的网站| 国产乱来视频区| 美女被艹到高潮喷水动态| 日本黄大片高清| 国产 亚洲一区二区三区 | 青青草视频在线视频观看| 亚洲人与动物交配视频| 亚洲人成网站在线观看播放| 国产黄色免费在线视频| 美女xxoo啪啪120秒动态图| 麻豆成人午夜福利视频| 国产在线男女| 男人舔奶头视频| 亚洲国产欧美人成| 亚洲精品成人av观看孕妇| 可以在线观看毛片的网站| 大话2 男鬼变身卡| 国产成人福利小说| 久久人人爽人人片av| 久久久精品免费免费高清| 国产免费一级a男人的天堂| 爱豆传媒免费全集在线观看| 好男人在线观看高清免费视频| 国产高清三级在线| 午夜福利高清视频| 精品一区在线观看国产| 亚洲一区高清亚洲精品| 日韩,欧美,国产一区二区三区| 国产精品福利在线免费观看| 国产高清有码在线观看视频| 丝瓜视频免费看黄片| 大香蕉久久网| 婷婷色综合大香蕉| videossex国产| av线在线观看网站| 成年女人看的毛片在线观看| 一级a做视频免费观看| 国产片特级美女逼逼视频| 一级爰片在线观看| 91久久精品电影网| 乱人视频在线观看| 欧美成人精品欧美一级黄| 十八禁网站网址无遮挡 | 国产成人a区在线观看| 在现免费观看毛片| 天堂俺去俺来也www色官网 | 亚洲丝袜综合中文字幕| 成人一区二区视频在线观看| 美女被艹到高潮喷水动态| 特级一级黄色大片| 夫妻性生交免费视频一级片| ponron亚洲| 精品人妻视频免费看| 免费电影在线观看免费观看| 激情五月婷婷亚洲| 两个人视频免费观看高清| 日本一二三区视频观看| 国产精品一区www在线观看| 中文字幕制服av| 联通29元200g的流量卡| av在线观看视频网站免费| 一级毛片久久久久久久久女| av线在线观看网站| 亚洲经典国产精华液单| 亚洲av国产av综合av卡| 男人舔女人下体高潮全视频| 精品午夜福利在线看| 性插视频无遮挡在线免费观看| 成人av在线播放网站| 免费看av在线观看网站| 欧美97在线视频| 精品国内亚洲2022精品成人| av.在线天堂| 菩萨蛮人人尽说江南好唐韦庄| 免费看美女性在线毛片视频| 国产精品一区www在线观看| 午夜精品一区二区三区免费看| 日韩在线高清观看一区二区三区| 成人综合一区亚洲| 国产成人精品福利久久| 91久久精品电影网| 日韩欧美精品v在线| 国产视频首页在线观看| 国产老妇伦熟女老妇高清| 免费黄网站久久成人精品| 精品一区二区三卡| 国产成人精品一,二区| 日韩欧美国产在线观看| 秋霞伦理黄片| 成人午夜精彩视频在线观看| 可以在线观看毛片的网站| 欧美高清成人免费视频www| 国产精品.久久久| 国内少妇人妻偷人精品xxx网站| 国产精品福利在线免费观看| 日韩制服骚丝袜av| 亚洲精品国产成人久久av| 在线观看美女被高潮喷水网站| 高清av免费在线| 精品久久久精品久久久| 18禁动态无遮挡网站| 美女被艹到高潮喷水动态| 亚洲欧美一区二区三区黑人 | 欧美激情国产日韩精品一区| 国产av码专区亚洲av| 国产精品无大码| 狂野欧美激情性xxxx在线观看| 亚洲va在线va天堂va国产| 青春草国产在线视频| 老师上课跳d突然被开到最大视频| 看黄色毛片网站| 国产成人精品福利久久| freevideosex欧美| 亚洲欧洲国产日韩| 综合色丁香网| 99热这里只有是精品在线观看| 国产淫语在线视频| 伊人久久精品亚洲午夜| 国产永久视频网站| 26uuu在线亚洲综合色| 91av网一区二区| 3wmmmm亚洲av在线观看| 搡女人真爽免费视频火全软件| www.色视频.com| 久久这里只有精品中国| 亚洲国产精品sss在线观看| 亚州av有码| 综合色丁香网| 日日摸夜夜添夜夜爱| 日日干狠狠操夜夜爽| 性色avwww在线观看| 久久精品国产亚洲网站| 午夜免费观看性视频| 久久久欧美国产精品| 日韩一区二区视频免费看| 亚洲人成网站高清观看| 亚洲无线观看免费| 特级一级黄色大片| 麻豆成人av视频| 亚洲国产日韩欧美精品在线观看| 一区二区三区高清视频在线| 亚洲av.av天堂| 国产在视频线精品| 国产免费视频播放在线视频 | 亚洲最大成人手机在线| 一区二区三区四区激情视频| 97超视频在线观看视频| 一级二级三级毛片免费看| 欧美xxxx黑人xx丫x性爽| 一二三四中文在线观看免费高清| 69av精品久久久久久| 亚洲精品国产av成人精品| 久99久视频精品免费| 免费在线观看成人毛片| 91精品国产九色| 99热这里只有是精品50| 国产精品一区二区三区四区免费观看| 国产精品一区二区在线观看99 | 国产av不卡久久| 亚洲精品影视一区二区三区av| 亚洲四区av| 亚洲欧美中文字幕日韩二区| 婷婷色av中文字幕| 欧美成人午夜免费资源| 成人一区二区视频在线观看| 欧美人与善性xxx| 国产熟女欧美一区二区| 麻豆久久精品国产亚洲av| 国产乱人视频| 久久99蜜桃精品久久| 一级毛片 在线播放| av又黄又爽大尺度在线免费看| 一级毛片电影观看| 91久久精品国产一区二区成人| 欧美成人一区二区免费高清观看| 在线免费十八禁| 建设人人有责人人尽责人人享有的 | 亚洲精品中文字幕在线视频 | 在线观看美女被高潮喷水网站| 性插视频无遮挡在线免费观看| 国产精品美女特级片免费视频播放器| 亚洲国产成人一精品久久久| 成人综合一区亚洲| 日本-黄色视频高清免费观看| 日韩人妻高清精品专区| 亚洲av免费在线观看| 最近视频中文字幕2019在线8| 国产淫片久久久久久久久| 亚洲成人一二三区av| 小蜜桃在线观看免费完整版高清| 久久久久久久久久久免费av| 2021天堂中文幕一二区在线观| 亚洲国产av新网站| 日韩强制内射视频| 国内精品宾馆在线| 蜜桃亚洲精品一区二区三区| 国产 一区 欧美 日韩| 亚洲性久久影院| 欧美区成人在线视频| 我的老师免费观看完整版| 亚洲欧洲国产日韩| 精品久久国产蜜桃| 91在线精品国自产拍蜜月| 国产麻豆成人av免费视频| 别揉我奶头 嗯啊视频| 91精品一卡2卡3卡4卡| av福利片在线观看| 日韩av在线免费看完整版不卡| 亚洲欧洲国产日韩| 舔av片在线| 午夜免费激情av| 中文字幕亚洲精品专区| 人人妻人人看人人澡| 精品国产露脸久久av麻豆 | 一级毛片电影观看| 亚洲欧美清纯卡通| 成年av动漫网址| 97超碰精品成人国产| 2022亚洲国产成人精品| 免费电影在线观看免费观看| 成人午夜高清在线视频| 精品久久久久久久久久久久久| 在线天堂最新版资源| 国产av不卡久久| 久99久视频精品免费| 色5月婷婷丁香| 国产免费一级a男人的天堂| 国产成人福利小说| 日本一二三区视频观看| 国产色爽女视频免费观看| 精品国产一区二区三区久久久樱花 | 国产亚洲最大av| 男人狂女人下面高潮的视频| 欧美最新免费一区二区三区| 国产男人的电影天堂91| 精品一区二区三区视频在线| 一级爰片在线观看| 91久久精品电影网| 国产 亚洲一区二区三区 | 99九九线精品视频在线观看视频| 蜜桃亚洲精品一区二区三区| 成人亚洲精品一区在线观看 | av女优亚洲男人天堂| 亚洲色图av天堂| 最近视频中文字幕2019在线8| 黄色欧美视频在线观看| 亚洲综合色惰| 久久精品国产鲁丝片午夜精品| 亚洲欧美精品专区久久| 午夜激情福利司机影院| 22中文网久久字幕| 国产精品熟女久久久久浪| 亚洲成色77777| 超碰av人人做人人爽久久| 啦啦啦韩国在线观看视频| 99热网站在线观看| 伊人久久国产一区二区| 精华霜和精华液先用哪个| 一级黄片播放器| 日本-黄色视频高清免费观看| 91精品伊人久久大香线蕉| 亚洲性久久影院| 夫妻午夜视频| 日韩欧美一区视频在线观看 | 欧美日本视频| 亚洲最大成人av| 精品一区二区三卡| 亚洲av成人av| 国产日韩欧美在线精品| 国产精品国产三级国产av玫瑰| 狠狠精品人妻久久久久久综合| 国产三级在线视频| 天堂俺去俺来也www色官网 | 久久久久精品性色| 亚洲电影在线观看av| 一个人观看的视频www高清免费观看| 亚洲性久久影院| 激情五月婷婷亚洲| 亚洲人成网站在线观看播放| 九色成人免费人妻av| 亚洲天堂国产精品一区在线| 久久久久久伊人网av| 久久久久久久大尺度免费视频| 婷婷色麻豆天堂久久| 男人爽女人下面视频在线观看| 国产av码专区亚洲av| 91精品伊人久久大香线蕉| 久久精品国产亚洲av涩爱| 2018国产大陆天天弄谢| 成人一区二区视频在线观看| 亚洲内射少妇av| 日本一本二区三区精品| 国产 亚洲一区二区三区 | 亚洲av不卡在线观看| 亚洲激情五月婷婷啪啪| 久久精品夜色国产| 亚洲av国产av综合av卡| 国产乱来视频区| 日韩人妻高清精品专区| 三级毛片av免费| 国产精品综合久久久久久久免费| 久久久久精品性色| 天天躁夜夜躁狠狠久久av| 99久国产av精品国产电影| 九九在线视频观看精品| 午夜福利视频1000在线观看| 亚洲欧美精品自产自拍| 精品欧美国产一区二区三| 你懂的网址亚洲精品在线观看| 六月丁香七月| 人体艺术视频欧美日本| 国产亚洲av嫩草精品影院| 免费av不卡在线播放| 色播亚洲综合网| 看免费成人av毛片| 亚洲aⅴ乱码一区二区在线播放| 久久精品国产亚洲av涩爱| 一级毛片久久久久久久久女| 免费看光身美女| 亚洲av成人av| 成人一区二区视频在线观看| 国产精品日韩av在线免费观看| 青春草视频在线免费观看| 亚洲精品色激情综合| 精品人妻一区二区三区麻豆| 久久精品久久久久久噜噜老黄| 欧美成人精品欧美一级黄| 少妇人妻一区二区三区视频| 干丝袜人妻中文字幕| 免费看a级黄色片| 青春草国产在线视频| 国产av在哪里看| 少妇熟女欧美另类| 亚洲欧美精品专区久久| 欧美 日韩 精品 国产| 中文欧美无线码| 日韩一区二区三区影片| 中文欧美无线码| 又爽又黄无遮挡网站| 街头女战士在线观看网站| 国产乱来视频区| 日产精品乱码卡一卡2卡三| 韩国av在线不卡| 蜜臀久久99精品久久宅男| 青春草国产在线视频| 日本与韩国留学比较| 成年免费大片在线观看| 美女大奶头视频| 99久国产av精品| 精品久久久久久久久亚洲| 久久久久久久大尺度免费视频| 看非洲黑人一级黄片| 欧美 日韩 精品 国产| 黄片wwwwww| 中文字幕亚洲精品专区| 色综合亚洲欧美另类图片| 日韩欧美国产在线观看| 国产男人的电影天堂91| 波多野结衣巨乳人妻| 日韩强制内射视频| 一个人看视频在线观看www免费| 青青草视频在线视频观看| 精品少妇黑人巨大在线播放| 毛片一级片免费看久久久久| 国产精品久久久久久久电影| 国产片特级美女逼逼视频| 国产爱豆传媒在线观看| 免费在线观看成人毛片| 亚洲成人中文字幕在线播放| 99久久人妻综合| 色综合亚洲欧美另类图片| 亚洲美女搞黄在线观看| 国产精品福利在线免费观看| 天天躁日日操中文字幕| 一区二区三区四区激情视频| 国产色婷婷99| 亚洲国产精品专区欧美| 国产69精品久久久久777片| 两个人的视频大全免费| 婷婷色综合www| 色综合色国产| 最近视频中文字幕2019在线8| 国产色婷婷99| 七月丁香在线播放| 精品久久久久久成人av| 日本午夜av视频| 建设人人有责人人尽责人人享有的 | 久久久亚洲精品成人影院| 最近中文字幕高清免费大全6| 久久精品熟女亚洲av麻豆精品 | 国产高清有码在线观看视频| 欧美最新免费一区二区三区| 高清欧美精品videossex| 国产精品一区二区性色av| 国产精品美女特级片免费视频播放器| 亚洲乱码一区二区免费版| 亚洲国产成人一精品久久久| 免费电影在线观看免费观看| 国产激情偷乱视频一区二区| 天美传媒精品一区二区| 国产高清不卡午夜福利| av女优亚洲男人天堂| 午夜日本视频在线| 欧美成人精品欧美一级黄| 日本wwww免费看| 国产精品麻豆人妻色哟哟久久 | 伊人久久精品亚洲午夜| 成人无遮挡网站| 永久网站在线| 久久人人爽人人片av| 美女大奶头视频| 99久久人妻综合| 国产成年人精品一区二区| 久久久精品免费免费高清| 超碰av人人做人人爽久久| 国产精品.久久久| 亚洲精品国产av成人精品| 成人毛片a级毛片在线播放| a级毛色黄片| av国产免费在线观看| 亚洲美女搞黄在线观看| 亚洲av成人av| 欧美人与善性xxx| 欧美成人a在线观看| 午夜福利在线观看免费完整高清在| 亚洲av日韩在线播放| 亚洲最大成人手机在线| 汤姆久久久久久久影院中文字幕 | 亚洲精品自拍成人| 亚洲精品456在线播放app| 日韩制服骚丝袜av| 成年女人在线观看亚洲视频 | 又爽又黄无遮挡网站| 草草在线视频免费看| 免费少妇av软件| 国产视频首页在线观看| 国产精品.久久久| 久久国内精品自在自线图片| 国产精品国产三级专区第一集| 午夜福利成人在线免费观看| av又黄又爽大尺度在线免费看| 久久久久久久久中文| 啦啦啦中文免费视频观看日本| 美女脱内裤让男人舔精品视频| 国产精品一区www在线观看| 亚洲成人精品中文字幕电影| 尤物成人国产欧美一区二区三区| 麻豆国产97在线/欧美| 熟妇人妻久久中文字幕3abv| 插阴视频在线观看视频| 日韩av在线免费看完整版不卡| 极品教师在线视频| 亚洲自偷自拍三级| 人妻一区二区av| 欧美xxxx黑人xx丫x性爽| 中文天堂在线官网| 如何舔出高潮| 亚洲熟妇中文字幕五十中出| 国产精品99久久久久久久久| 最近手机中文字幕大全| av网站免费在线观看视频 | 亚洲av国产av综合av卡| 99热这里只有精品一区| 亚洲av成人av| 日韩国内少妇激情av| 男插女下体视频免费在线播放| 亚洲av中文av极速乱| 成年av动漫网址| 少妇的逼好多水| 高清视频免费观看一区二区 | 汤姆久久久久久久影院中文字幕 | 美女大奶头视频| 老师上课跳d突然被开到最大视频| 欧美另类一区| 国产精品.久久久| 麻豆成人午夜福利视频| 五月伊人婷婷丁香| 国产免费又黄又爽又色| 搡老妇女老女人老熟妇| 成年女人看的毛片在线观看| 女人被狂操c到高潮| 一级毛片 在线播放| 亚洲精华国产精华液的使用体验| 好男人视频免费观看在线| 男的添女的下面高潮视频| 18禁动态无遮挡网站| 欧美精品国产亚洲| 亚洲欧美日韩东京热| 婷婷色综合www| 亚洲精品,欧美精品| 日韩欧美国产在线观看| 欧美性猛交╳xxx乱大交人| 波野结衣二区三区在线| 非洲黑人性xxxx精品又粗又长| 搡女人真爽免费视频火全软件| 秋霞伦理黄片| 欧美成人a在线观看| 国产乱人视频| 国产在线一区二区三区精| 激情五月婷婷亚洲| 国产高清不卡午夜福利| 日韩一区二区三区影片| av免费在线看不卡| 人妻一区二区av| 午夜福利视频1000在线观看| 国产精品无大码| 又黄又爽又刺激的免费视频.| 欧美一区二区亚洲| 天堂中文最新版在线下载 | videos熟女内射| 最近视频中文字幕2019在线8| 大陆偷拍与自拍| 国产视频内射| 爱豆传媒免费全集在线观看| 久久精品国产亚洲av涩爱| 男人和女人高潮做爰伦理| or卡值多少钱| 99视频精品全部免费 在线| 国产视频内射| 亚洲精品色激情综合| 不卡视频在线观看欧美| 久久久久精品性色| 热99在线观看视频| 成人综合一区亚洲| 一二三四中文在线观看免费高清| 中文字幕av成人在线电影| 色尼玛亚洲综合影院| 舔av片在线| 欧美日韩一区二区视频在线观看视频在线 | 嫩草影院入口| 午夜日本视频在线| 老师上课跳d突然被开到最大视频| 国产精品女同一区二区软件| 日本黄大片高清| 欧美极品一区二区三区四区| 久久久精品94久久精品| 国产毛片a区久久久久| 熟女人妻精品中文字幕| 草草在线视频免费看| 在线播放无遮挡| 免费观看的影片在线观看| 美女大奶头视频| 可以在线观看毛片的网站| 大片免费播放器 马上看| 亚洲av国产av综合av卡| 真实男女啪啪啪动态图| 一夜夜www| 午夜福利高清视频| 尤物成人国产欧美一区二区三区| 免费看美女性在线毛片视频| 1000部很黄的大片| 亚洲美女搞黄在线观看| 亚洲av电影在线观看一区二区三区 | 亚洲欧美一区二区三区黑人 | 国产精品一区二区三区四区久久| 久久久久国产网址| 51国产日韩欧美| 丰满人妻一区二区三区视频av| 国产精品99久久久久久久久| 成人av在线播放网站| 久久久成人免费电影| 高清视频免费观看一区二区 | 免费观看a级毛片全部| 可以在线观看毛片的网站| 97热精品久久久久久| 亚洲欧美日韩无卡精品| 精品一区二区三卡| 18禁在线无遮挡免费观看视频| 久久99蜜桃精品久久| 久久精品熟女亚洲av麻豆精品 | 久久久久国产网址| 51国产日韩欧美| 亚洲精品乱久久久久久| 日本熟妇午夜| 日韩 亚洲 欧美在线| 国产精品一及| 国内精品一区二区在线观看| 秋霞在线观看毛片| 国产一区亚洲一区在线观看| 国产白丝娇喘喷水9色精品| 国产亚洲一区二区精品| 少妇的逼好多水| 欧美区成人在线视频| 99久国产av精品| 91久久精品国产一区二区三区| 亚洲第一区二区三区不卡| 内地一区二区视频在线| 99九九线精品视频在线观看视频| 午夜福利网站1000一区二区三区|